In:
Science Translational Medicine, American Association for the Advancement of Science (AAAS), Vol. 14, No. 637 ( 2022-03-23)
Abstract:
Interferon regulatory factor 3 (IRF3) has been linked to metabolic dysregulation in obesity and nonalcoholic fatty liver disease (NAFLD), but its exact role in this context is unclear. Patel et al. report that hepatic IRF3 transcriptionally regulates Ppp2r1b , with downstream effects on glucose homeostasis via AMPK. Hepatocyte-specific knockout of IRF3 in high-fat diet–fed mice affected glycemic control only, uncoupled from steatosis. Antisense targeting of Irf3 improved insulin-mediated metabolic responses in obese mice, demonstrating a proof-of-principle therapeutic strategy. Enhanced hepatic activation of IRF3 in patients with NAFLD and obesity decreased after bariatric surgery, suggesting relevance to humans.
Type of Medium:
Online Resource
ISSN:
1946-6234
,
1946-6242
DOI:
10.1126/scitranslmed.abh3831
Language:
English
Publisher:
American Association for the Advancement of Science (AAAS)
Publication Date:
2022
Permalink